University of Michigan Rogel Cancer Center
320
40
54
178
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
25.9%
83 terminated/withdrawn out of 320 trials
68.2%
-18.3% vs industry average
2%
6 trials in Phase 3/4
68%
121 of 178 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (320)
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Role: lead
Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
Role: lead
Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients
Role: lead
SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners
Role: lead
Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation
Role: lead
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
Role: lead
A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial
Role: lead
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Role: lead
Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial
Role: lead
CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer
Role: lead
Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
Role: lead
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
Role: lead
A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
Role: lead
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
Role: lead
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
Role: lead
A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy
Role: lead
Feasibility of Virtual, Tailored, Music-Based Relaxation for Anxiety in Adolescent and Young Adult Cancer Survivors
Role: lead
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
Role: lead
Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma
Role: lead
Michigan Genetic Hereditary Testing (MiGHT)
Role: lead